Bridgebio Pharma Is A Biopharmaceutical Company Based In Palo Altocaliforniafounded In 2015The Company Is Dedicated To Discoveringcreatingtestingand Delivering Innovative Medicines For Patients With Genetic Diseases And Cancers That Have Clear Genetic Factorsbridgebio Operates Globallywith A Presence In The U S Canadafrancegermanyswitzerlandand The Uk The Company Offers Several Therapiesincluding Acoramidis For Transthyretin Amyloidosisnulibry For Molybdenum Cofactor Deficiencyand Truseltiqa Precision Oncology Therapybridgebio S Pipeline Includes Programs In Precision Cardiorenalmendelian Disordersgene Therapyand Oncologyfocusing On Conditions With Significant Unmet Medical Needsrecentlybridgebio Secured Up To $1 25 Billion In Capital To Enhance The Development And Commercialization Of Its Genetic Medicinesreflecting Its Commitment To Translating Scientific Advances Into Clinical Solutions Efficiently
